Sitagliptin Phosphate Tablets

Form: Tablets

Strength: 25 mg, 50 mg, 100 mg

Reference Brands: Januvia(US & EU)

Category: Diabetes

Sitagliptin, marketed under the brand name Januvia, is a DPP-4 inhibitor approved for managing type 2 diabetes mellitus. In the USA, the FDA approved Sitagliptin in 2006, and it remains under brand protection with limited generic availability. In the EU, it received EMA approval in 2007 and is available in multiple strengths (25 mg, 50 mg, 100 mg). Sitagliptin is used as monotherapy or in combination with other antidiabetic agents. Pharmacovigilance data confirms a favorable safety profile. With patent expirations approaching in some regions, generic versions are beginning to enter select EU markets. Widely sourced via platforms like Pharmatradz.com.